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Abstract. The blood‑brain barrier (BBB) constitutes an effi-
cient organization of tight junctions that limits the delivery of 
tumor to the brain. The principal tight junction protein in BBB 
is claudin-5 (CLDN5), but its mechanism of action remains 
largely unknown. Long non-coding RNAs (lncRNAs) are aber-
rantly expressed in many cancers, some lncRNAs play key roles 
in regulating BBB permeability and are involved in tumor brain 
metastasis. In particular, lncRNAs can function as competing 
endogenous RNAs (ceRNAs). Herein, we investigated whether 
ceRNA dysregulation is associated with alterations of the level 
of CLDN5 in human brain vascular endothelial hCMEC/D3 
cells. The Affymetrix Human Transcriptome Array 2.0 and 
Affymetrix GeneChip miRNA 4.0 Array were used to detect 
the expression levels of 2,578 miRNAs, 22,829 lncRNAs, and 
44,699 mRNAs in pLL3.7-CLDN5-transfected and pLL3.7 
control hCMEC/D3 cells. The distinctly expressed miRNAs, 
lncRNAs, and mRNAs were subjected to construction of 
miRNA-lncRNA-mRNA interaction network. A total of 41 
miRNAs, 954 lncRNAs, and 222 mRNAs were found to be 
differentially expressed between the CLDN5-overexpressing 
and control group. 148 lncRNA acting as ceRNAs were identi-
fied based on the miRNA‑lncRNA‑mRNA interaction network. 
The function of differential mRNA in the network was deter-
mined by GO and pathway analysis. The potential roles of the 
27 ceRNAs were revealed, the possible biology functions of 
these regulatory ceRNAs mainly included tight junction, focal 
adhesion, cell-cell adhesion, cell growth and apoptosis. The 
identified sets of miRNAs, lncRNAs and mRNAs specific to 
CLDN5-overexpressing hCMEC/D3 cells were verified by 
quantitative real-time RT-PCR experiment. Our study predicts 
the biological functions of a multitude of ceRNAs associated 
with the alteration of CLDN5 in brain vascular endothelial 
cells. Our data suggest that these dysregulated ceRNAs, in 
conjunction with the high CLDN5 levels, could serve as useful 
targets of prevention of brain metastasis formation. Further 
studies are warranted to determine the role of these ceRNAs 
in facilitating the function of CLDN5 in brain-tumor barrier.
Introduction
The blood-brain barrier (BBB) is located at the level of 
cerebral capillaries in the forefront of the defense line of 
the central nervous system (CNS) and restricts the flow of 
essential components into and out of the CNS (1,2). The most 
important cellular elements of the BBB consist of endothelial 
cell, astrocyte, pericyte, and the adjacent neurons (3). The 
endothelial cells are connected by junction complex, in which 
tight junctions (TJs) play a significant role. Key components of 
the TJs are the transmembrane protein, and the best character-
ized TJs in cerebral endothelial cells are occluding, claudins 
and junctional adhesion molecules (JAMs) (4). 
Brain metastases constitute a significant part of intracranial 
tumors. The majority of brain metastases originate from lung 
cancer, breast cancer and malignant melanoma (5). Metastatic 
cells invading the CNS parenchyma, however, have to pass 
the BBB. Since brain metastases represent a great therapeutic 
challenge, it is important to understand the mechanisms of 
the interaction of tumor cells with the BBB to find targets of 
prevention of brain metastasis formation. 
The attachment of tumor cells to brain endothelial cells and 
the transendothelial migration of tumor cells are the key step in 
brain metastasis, plenty of molecules and signal pathways partic-
ipated in this complicated process. Claudins are small proteins 
(20-27 kDa) (6), and the principal claudin in brain endothelial 
cells is claudin-5 (CLDN5) (7). CLDN5 forms the backbone of 
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the tight junction and was shown to be solely responsible for 
the paracellular barrier that exists between epithelial cell, and 
absence of CLDN5 leads to a selective opening of the BBB to 
molecules smaller than 800 Da (8). CLDN5 has also recently 
been shown to directly play a role in the interaction of metastatic 
tumor cells and brain endothelial cells (9), but its mechanism of 
action remains largely unknown. 
Recent studies have described a complicated interplay among 
diverse RNA molecules, including coding and non-coding 
RNAs (10,11). Human genome generates plurality of regulatory 
RNAs that are either long non-coding RNAs (lncRNAs) or small 
non-coding RNA such as microRNAs (miRNAs). LncRNAs 
are defined as >200 nucleotides and unable to be translated 
into proteins. Accumulating data show that lncRNAs are major 
regulators of physiological and disease-related gene expression 
through various mechanisms. The dysregulated lncRNA expres-
sion has been documented in various disease states, and their 
tissue specificity makes them attractive candidates as diagnostic 
or prognostic biomarkers or therapeutic agents. miRNAs are 
endogenous ~22 nucleotide RNAs, which post-transcriptionally 
regulate the gene expression through interaction between their 
5' end and the 3' untranslated region (uTR) of mRNA. The 
functions of miRNA have been elucidated extensively and it 
participates in regulating a variety of cellular events (12-14). 
Recent studies indicated that some specific lncRNAs can serve 
as competitive endogenous RNAs (ceRNA) to control miRNAs 
available for binding with targets, functionally sequester 
miRNAs and as miRNA sponges, thereby alleviating the inhibi-
tory effect of miRNA on their respective mRNA targets (15). 
The function introduces an extra layer of complexity in the 
miRNA-target interaction network. The complexity and diver-
sity of potential ceRNA interactions have been described with 
the identification of abundant lncRNAs. Understanding this 
novel RNA interaction will lead to significant insight into gene 
regulatory networks in a variety of cell process (16-19). 
The involvement of ceRNA regulation as a factor of 
CLDN5 modulation in brain vascular endothelial cells has not 
been previously investigated. To gain further understanding 
of how CLDN5 mediates its activities in tumor brain metas-
tasis, herein, in this study, we examined changes in globe 
mRNA, miRNA, lncRNA gene expression when CLDN5 was 
overexpressed in the human brain vascular endothelial cell 
line, hCMEC/D3. We have identified a number of ceRNAs 
whose expression levels were altered as a consequence of high 
CLDN5 expression. The identified sets of lncRNA, miRNA 
and mRNA specific to CLDN‑5‑overexpressing hCMEC/D3 
cells were subsequently confirmed by quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR). 
Materials and methods
Cell culture and transduction. Human brain vascular endo-
thelial hCMEC/D3 cells were obtained from Institut Cochin 
(université René Descartes, Paris, France). Cells were cultured 
in the EBM-2 medium supplemented with EGMTM-2 Bullet 
kit (Lonza, Walkersville, NJ, USA) in a humidified 37˚C incu-
bator with an atmosphere of 5% CO2. 
In the overexpression experiment, the CLDN5 expression 
vector was constructed by inserting a human CLDN5 cDNA 
into pLL3.7-GFP. CLDN5-pLL3.7 or control pLL3.7 vector 
were transfected into 293T cells using Lipofectamine 3000 
(Thermo Fisher Scientific, Inc., Waltham, MA, USA). Super‑
natant containing retroviruses was collected and concentrated 
48 and 72 h later and was used for the transduction. The 
hCMEC/D3 cells were transducted with the virus-containing 
medium plus 8 µg/ml polybrene. Forty-eight hours after 
beginning the transduction, GFP+ cells were sorted and the 
expression of CLDN5 was confirmed by qRT‑PCR. 
RNA extraction. Total RNA of CLDN5-overexpressing and 
control hCMEC/D3 cells were extracted using TRIzol Reagent 
(Invitrogen Life Technologies, Carlsbad, CA, uSA) according 
to the manufacturer's protocol. RNA quantity was evaluated 
by the 28S/18S ratio and RNA Integrity Number (RIN) was 
analyzed on the Agilent 2100 bioanalyzer using the Eukaryote 
Total RNA Nano assay (Agilent Technologies, waldbronn, 
Germany). RNA purity was evaluated by the A260/A280 ratio 
using an RNA 6000 Nano Spectrophotometer (Agilent). 
miRNA, mRNA, lncRNA microarray and computational anal‑
ysis. For mRNA and lncRNA expression profiling, Affymetrix 
Human Transcriptome Array 2.0 (HTA 2.0) (Thermo Fisher 
Scientific, Inc.) was used. For miRNA expression profiling, 
Affymetrix GeneChip miRNA 4.0 Array (Thermo Fisher 
Scientific, Inc.) was used. After hybridization and washing, the 
arrays were scanned by an Affymetrix Microarray Scanner 
(Applied Biosystems, Grand Island, NY, uSA). Raw data 
of HTA 2.0 were extracted and normalized by Affymetrix® 
Transcriptome Analysis Console (TAC) Software (Thermo 
Fisher Scientific, Inc.). miRNA QC Tool software (Thermo 
Fisher Scientific, Inc.) was used for miRNA 4.0 array data 
summarization, normalization, and quality control.
Difference analysis. Two-class differential was used to 
determine the differentially expressed miRNA, lncRNA and 
mRNA between the pLL3.7-CLDN5-transfected group (n=3) 
and pLL3.7 control group (n=3). The random variance model 
(RVM) t‑test was applied to filter the differentially expressed 
genes for it can effectively raise the degrees of freedom in 
cases of small samples. The false discovery rate (FDR) was 
calculated to correct the P-value. P-values <0.05 and FDR 
<0.05 were considered as significant differences. 
The differentially expressed probe sets were imported into 
Cluster and Tree View to perform hierarchical cluster analysis 
(HCA).
Construction of lncRNA‑mRNA co‑expression network. we 
utilized the expression profile of different lncRNAs and differ-
ence mRNAs to construct the lncRNA-mRNA network. This 
network distinctly revealed the relation between the lncRNAs 
and mRNAs, found the key regulation and ʻ interaction venationʼ 
thoroughly. This network assimilated the scale-free property of 
the huge data, to simulate the scale-free relation by the inter-
action between lncRNAs and mRNAs and interaction among 
themselves, and that is the correlation of pairwise expression. 
In order to get reliable and accurate relation of gene interaction 
and lncRNA regulation function, we recommend the number 
of no less than 30 and the number of genes no less than 200.
For each pair of mRNA-lncRNA, mRNA-mRNA, or 
lncRNA-lncRNA, we calculated the Pearson correlation 
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Table I. The primers of miRNA, mRNA, and lncRNA for qRT-PCR.
Primers Sequence (5'-3')
miR-297 RT: TCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGACATGCACA
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGATGTATGTGTGCAT
miR-610 RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGATCCCAGCA
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGTGAGCTAAATGTG
miR-767-5p RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGACATGCTCA
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGTGCACCATGGTTGTCT
miR-329-3P RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAAAAGAGGT
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGAACACACCTGGTTAA
miR-921 RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAATCCTG
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGCTAGTGAGGGACAGAACC
miR-127-5p RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAATCAGAGC
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGCTGAAGCTCAGAGGG
miR-4786-5p RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGTGCATC
 F: CTCAACTGGTGTCGTGGAGT
 R: ACACTCCAGCTGGGTGAGACCAGGACTGG
POTED F: GTGGTGCTGTCACTGCTTCCC
 R: CGCTGTGGTCGTAGTCTCCC
TMPRSS15 F: GGCAGCTCAAGACATCACCC
 R: GCCGCCATAATACAGACCCA
EFNB2 F: GAGCAGGAAGCCGATGTGAC
 R: GGGAAAACCCAACGCAGAAA
IL7R F: TGAGTGTCGTCTATCGGGAAGG
 R: CTGGCGGTAAGCTACATCGTG
AMTN F: CAGACCCACCCATTGACCCT
 R: GGATTAGCCCCTGCCTGACT
PIK3CG F: GCCACTGATCCACTTAACCCTC
 R: AATTTCTTGCTGTCCCCATTTC
CLDN1 F: TGAGGATGGCTGTCATTGGG
 R: ACCTGGCATTGACTGGGGTC
OCLN F: TCTCCCTCCCTGCTTCCTCT
 R: GCAATGCCCTTTAGCTTCCA
ENST00000427446 F: ATTATCAGCTCGTGAGTACGGACAT
 R: GAAAACATGGAAGCTCTATTTGGTC
n342142 F: AGAAAGAGCCAACAACTCCTACAGA
 R: TGAGTGGTTCAGATTTAGGCACAGA
TCONS_00017956- F: GATAATTCCGTTTGACTCCGTTTGA
XLOC_008786 R: CTAATGGAATCGCATGGTATCTTCA
ENST00000425979 F: CAAAGGCAAAGATTGGAGTTGTACT
 R: ACGAATCCTTGCTTGTTTCTTCTAG
TCONS_00028418- F: CTTTCTGGGTCTTCTGTTTCACGAT
XLOC_013771 R: TTTCTGTTCAAGTTTGAGGGTCCTG
n338895 F: GCACGGTATCATTACTCCCGTTTTA
 R: AACCTCTGATAAGGACAAGCAACCC
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and chose the significant correlation pairs to construct the 
network (20). The clustering coefficient represents the density 
of each gene with the adjacent gene, and the larger the clus-
tering coefficient, the greater importance the gene has in 
regulating the network.
Gene ontology and pathway analysis. A gene ontology (GO) 
analysis was applied to analyze the main functions of the 
mRNAs of miRNA‑lncRNA‑mRNA internets. Specifically, 
a two-side Fisher's exact test and a χ2 test were used to clas-
sify the GO category. we computed P-values of the GO 
for each differential gene. Enrichment provides a measure 
for the significant function: As the enrichment increases, 
the corresponding function is more specific. within the 
significant category, the enrichment Re was given as 
follows: Re=(nf/n)/(Nf/N), where nf is the number of flagged 
genes within the particular category, n is the total number 
of genes within the same category, Nf is the number of flagged 
genes in the entire microarray, and N is the total number of 
genes in the microarray.
Pathway analysis was used to identify the significant 
pathway of the differential mRNAs according to KEGG, 
Biocarta, and Reatome. we used Fisher's exact test and the 
χ2 test to select the significant pathway, and the threshold of 
Figure 2. Schematic overview of the work f low for construction of 
miRNA-lncRNA-mRNA interaction network. 
Table I. Continued.
Primers Sequence (5'-3')
n339695 F: ATTCTCCTGCCTCAGCCTCCCAAGT
 R: GTGCGGTGGCTCACGTCTGTAGTCC
TCONS_00022673-XLOC_010971 F: AACAGAAGCCCAGGGAGATAAAGAC
 R: TGGAAATGATCCTGGATTAGGAATG
Figure 1. Hierarchical clustering analysis of miRNA, LncRNA, and mRNA expression levels between pLL3.7-CLDN5-transfected group (n=3) and pLL3.7 
control group (n=3). (A) 41 miRNAs, (B) 954 lncRNAs and (C) 222 mRNAs are differentially expressed in overexpressing hCMEC/D3 cells, fold change 
≥1.2 or ≤0.8, P<0.05. Columns represent samples and rows respectively represent miRNA, lncRNA or mRNA probe sets. Red represents high expression, blue 
represents low expression, indicating expression above and below the median expression value across all the samples (log scale 2: From -0.5 to +0.5). 
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Table II. 146 lncRNAs as ceRNAs in the miRNA-lncRNA-mRNA interaction network. 
No. lncRNA accession No. lncRNA accession
  1 TCONS_l2_00014900-XLOC_l2_008262 75 n334798
  2 TCONS_l2_00020697-XLOC_l2_010802 76 n338832
  3 TCONS_00016931-XLOC_007962 77 n340212
  4 TCONS_l2_00016969-XLOC_l2_008979 78 n340287
  5 TCONS_00008436-XLOC_003882 79 n382215
  6 TCONS_l2_00016970-XLOC_l2_008980 80 n405896
  7 TCONS_l2_00017319-XLOC_l2_008977 81 n410552
  8 NR_002813 82 NR_027755
  9 TCONS_l2_00012202-XLOC_l2_006419 83 TCONS_00012035-XLOC_005569
10 n409500 84 TCONS_00014701-XLOC_006799
11 n341154 85 TCONS_00017991-XLOC_008840
12 TCONS_l2_00010766-XLOC_l2_005781 86 TCONS_00024504-XLOC_011823
13 n342063 87 ENST00000448869
14 n386722 88 ENST00000506895
15 TCONS_00003006-XLOC_001678 89 n326341
16 NR_024387 90 n332799
17 TCONS_00007677-XLOC_003770 91 n335107
18 TCONS_00019368-XLOC_009191 92 n335724
19 n409372 93 n337920
20 n342249 94 n338102
21 n408882 95 n338270
22 TCONS_00022673-XLOC_010971 96 n340792
23 n334377 97 n378134
24 NR_024076 98 n382996
25 NR_033360 99 n406201
26 NR_038399 100 n407038
27 TCONS_00016279-XLOC_007654 101 n408084
28 TCONS_00026192-XLOC_012669 102 n409198
29 TCONS_00028418-XLOC_013771 103 NR_036676
30 ENST00000440955 104 OTTHuMT00000318709
31 n341106 105 TCONS_00009631-XLOC_004772
32 n409178 106 TCONS_00012197-XLOC_005754
33 NR_027995 107 TCONS_00026389-XLOC_012738
34 TCONS_00011934-XLOC_005442 108 TCONS_l2_00020780-XLOC_l2_010854
35 TCONS_00028427-XLOC_013779 109 TCONS_l2_00025904-XLOC_l2_013423
36 TCONS_00011225-XLOC_005777 110 ENST00000422082
37 TCONS_00028805-XLOC_013878 111 ENST00000468202
38 n338895 112 ENST00000511994
39 n339264 113 ENST00000513211
40 n381942 114 ENST00000514265
41 NR_002808 115 ENST00000546710
42 TCONS_00020860-XLOC_010143 116 ENST00000550035
43 TCONS_00024807-XLOC_011645 117 n324907
44 TCONS_l2_00011136-XLOC_l2_006021 118 n325126
45 n338919 119 n325417
46 n339042 120 n325964
47 n341945 121 n332690
48 n342142 122 n333177
49 n411744 123 n333293
50 NR_038849 124 n335571
51 TCONS_00009713-XLOC_004905 125 n339266
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significance was defined by P‑value and FDR. The enrichment 
Re was calculated as indicated in the equation above.
qRT‑PCR analysis. Total RNA was reverse-transcribed with a 
PrimeScript™ RT reagent kit (Takara Biotechnology Co., Ltd., 
Dalian, China) for cDNA synthesis and genomic DNA removal. 
For miRNA detection, total RNA was reverse transcribed using 
miRNA specific primers. QPCR was performed according to 
the instructions of the SYBR premix Ex Taq™ II kit (Takara 
Biotechnology Co.) and carried out in the Takara real-time PCR 
system. GAPDH was used as lncRNA and mRNA control and 
U6 was used as a miRNA control. Gene‑specific primers were 
designed using primer designing tools primer 5.0. The primer 
sequences are listed in Table Ⅰ. The specificity of amplification 
was assessed by dissociation curve analysis, and the relative 
abundance of genes was determined with the 2-ΔΔCt method. All 
experiments were performed in triplicate.
Results
CLDN‑5 induces significantly altered miRNA, lncRNA and 
mRNA expression patterns in hCMEC/D3 cells. To explore the 
regulatory mechanism of CLDN5 on permeability of BBB, we 
stably transfected the hCMEC/D3 cells with pLL3.7-CLDN5 or 
pLL3.7, and then analyzed the changes of miRNA, lncRNA, and 
mRNA levels in CLDN-5-overexpressing hCMEC/D3 cells.
In terms of the miRBaseV20 Database, 2578 human 
miRNAs were authenticated on the Affymetrix GeneChip 
microRNA 4.0 Array. Based on the RefSeq, uCSC, 
GENCODES, MGC, lincRNAs TuCPs, lincRNAdb and 
uCSC lincRNA, annotations of lncRNAs and mRNAs, the 
probe sets covered 22, 829 lncRNAs and 44, 699 mRNAs on 
the Affymetrix GeneChip HTA 2.0 Array. 
The miRNA, lncRNA, and mRNA expression patterns were 
detected in pLL3.7-CLDN5-transfected group and pLL3.7 
control group. We identified 41 miRNAs, 954 lncRNAs, and 
222 mRNAs that had significant differential expression in the 
CLDN5-overexpressing group comparing with the control 
group (fold change ≥1.2 or ≤0.8, and P‑value <0.05). The 
hierarchical clustering analysis showed that with the differ-
entially expression of these miRNAs, lncRNAs and mRNAs, 
samples were non-random partitioned, they were divided into 
two groups (Fig. 1). Thus, the miRNA, lncRNA, and mRNA 
expression signatures identified here were likely to be repre-
sentative.
Construction of miRNA‑lncRNA‑mRNA interaction of network 
regulated by reinforced CLDN5 and identification lncRNAs 
acting as ceRNAs. The miRNA-lncRNA-mRNA interaction 
network was constructed according to the work flow summa-
rized in Fig. 2.
Firstly, the miRanda was applied to analyze the target 
mRNAs and lncRNAs of the 41 miRNAs, and then the inter-
action of these target mRNAs with distinct mRNAs and target 
lncRNAs with distinct lncRNAs, separately termed as target 
mRNAs (172 mRNAs, data not shown) and target lncRNAs 
Table II. Continued.
No. lncRNA accession No. lncRNA accession
52 ENST00000414772 126 n339695
53 ENST00000427446 127 n340730
54 ENST00000508925 128 n340955
55 ENST00000546560 129 n342367
56 n340540 130 n342493
57 n342109 131 n345192
58 n379390 132 n345550
59 n411650 133 n346330
60 TCONS_00028187-XLOC_013543 134 n346394
61 TCONS_l2_00021562-XLOC_l2_010625 135 n383730
62 n342193 136 n408256
63 n342616 137 n408302
64 n342622 138 n410892
65 n406194 139 n411520
66 n406899 140 NR_033752
67 n411603 141 NR_033826
68 OTTHuMT00000363702 142 OTTHuMT00000370627
69 TCONS_00016056-XLOC_007446 143 TCONS_00000861-XLOC_000086
70 TCONS_00022099-XLOC_010709 144 TCONS_00003277-XLOC_002089
71 TCONS_l2_00012572-XLOC_l2_006751 145 TCONS_00008003-XLOC_003469
72 ENST00000452532 146 TCONS_00017956-XLOC_008786
73 ENST00000507838 147 TCONS_00025335-XLOC_012147
74 n325350 148 TCONS_00029068-XLOC_013994
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Table III. The 95 feed-forward loops including miRNAs, lncRNAs and mRNAs.
No. miRNA lncRNA mRNA
  1 hsa-miR-4677-3p n325350 IGFBP3
  2 hsa‑miR‑487a‑3p TCONS_00012035‑XLOC_005569 PIK3CG
  3 hsa‑miR‑6760‑5p TCONS_00012035‑XLOC_005569 PIK3CG
  4 hsa‑miR‑3135b NR_038399 DOCK1
  5 hsa‑miR‑6760‑5p NR_038399 DOCK1
  6 hsa-miR-297 NR_033360 IGFBP3
  7 hsa-miR-4677-3p NR_033360 IGFBP3
  8 hsa-miR-297 TCONS_00009713-XLOC_004905 IGFBP3
  9 hsa-miR-4289 TCONS_00009713-XLOC_004905 IGFBP3
10 hsa-miR-619-5p TCONS_00009713-XLOC_004905 IGFBP3
11 hsa-miR-7-5p TCONS_00009713-XLOC_004905 IGFBP3
12 hsa‑miR‑4726‑5p TCONS_l2_00011136‑XLOC_l2_006021 DOCK1
13 hsa‑miR‑6760‑5p TCONS_l2_00011136‑XLOC_l2_006021 DOCK1
14 hsa‑miR‑323a‑3p TCONS_00003006‑XLOC_001678 CDKN1B
15 hsa‑miR‑3912‑5p TCONS_00003006‑XLOC_001678 CDKN1B
16 hsa‑miR‑543 TCONS_00003006‑XLOC_001678 CDKN1B
17 hsa‑miR‑6760‑5p TCONS_00003006‑XLOC_001678 CDKN1B
18 hsa‑miR‑7845‑5p TCONS_00003006‑XLOC_001678 CDKN1B
19 hsa-miR-3912-5p TCONS_00003006-XLOC_001678 PHLPP1
20 hsa-miR-6760-5p TCONS_00003006-XLOC_001678 PHLPP1
21 hsa-miR-7845-5p TCONS_00003006-XLOC_001678 PHLPP1
22 hsa-miR-297 TCONS_l2_00021562-XLOC_l2_010625 IGFBP3
23 hsa-miR-4289 TCONS_l2_00021562-XLOC_l2_010625 IGFBP3
24 hsa-miR-4677-3p TCONS_l2_00021562-XLOC_l2_010625 IGFBP3
25 hsa-miR-619-5p TCONS_l2_00021562-XLOC_l2_010625 IGFBP3
26 hsa-miR-7-5p TCONS_l2_00021562-XLOC_l2_010625 IGFBP3
27 hsa-miR-297 n409198 IGFBP3
28 hsa-miR-4677-3p n409198 IGFBP3
29 hsa-miR-3135b n406899 ARHGEF12
30 hsa-miR-4462 n406899 ARHGEF12
31 hsa-miR-654-3p n406899 ARHGEF12
32 hsa-miR-7845-5p n406899 ARHGEF12
33 hsa‑miR‑3135b TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
34 hsa‑miR‑323a‑3p TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
35 hsa‑miR‑329‑3p TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
36 hsa‑miR‑4462 TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
37 hsa‑miR‑4726‑5p TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
38 hsa‑miR‑6076 TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
39 hsa‑miR‑6760‑5p TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
40 hsa‑miR‑921 TCONS_l2_00014900‑XLOC_l2_008262 DOCK1
41 hsa-miR-6760-5p n346394 CADM1
42 hsa-miR-4665-5p ENST00000546560 PPARD
43 hsa‑miR‑323a‑3p TCONS_l2_00020697‑XLOC_l2_010802 CDKN1B
44 hsa‑miR‑3912‑5p TCONS_l2_00020697‑XLOC_l2_010802 CDKN1B
45 hsa‑miR‑543 TCONS_l2_00020697‑XLOC_l2_010802 CDKN1B
46 hsa‑miR‑6760‑5p TCONS_l2_00020697‑XLOC_l2_010802 CDKN1B
47 hsa‑miR‑7845‑5p TCONS_l2_00020697‑XLOC_l2_010802 CDKN1B
48 hsa-miR-4289 n335571 IGFBP3
49 hsa-miR-4278 ENST00000452532 PPARD
50 hsa-miR-3912-5p TCONS_l2_00020697-XLOC_l2_010802 PHLPP1
51 hsa-miR-4646-5p TCONS_l2_00020697-XLOC_l2_010802 PHLPP1
52 hsa-miR-6760-5p TCONS_l2_00020697-XLOC_l2_010802 PHLPP1
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(681 lncRNAs, data not shown). Of the target mRNAs and 
lncRNAs, the mRNAs and lncRNAs were selected which 
expression levels were negatively correlated with miRNA expres-
sion, and were termed the N&T mRNAs (152 mRNAs, data not 
shown) and N&T lncRNAs (618 lncRNAs, data not shown), and 
obtained the miRNA-mRNA, miRNA-lncRNA network. 
Secondly, according to the correlation of gene expres-
sion of 222 mRNAs and 954 lncRNAs, we constructed the 
lncRNA-mRNA co-expression network (data not shown).
At last, based on the interaction network of miRNA- 
mRNA, miRNA-lncRNA, and lncRNA-mRNA, we obtained 
1049 feed-forward loop networks and constructed the general 
Table III. Continued.
No. miRNA lncRNA mRNA
53 hsa-miR-7845-5p TCONS_l2_00020697-XLOC_l2_010802 PHLPP1
54 hsa‑miR‑4289 n333293 CDKN1A
55 hsa‑miR‑3135b n409500 DOCK1
56 hsa‑miR‑4462 n409500 DOCK1
57 hsa‑miR‑4726‑5p n409500 DOCK1
58 hsa‑miR‑6076 n409500 DOCK1
59 hsa‑miR‑6760‑5p n409500 DOCK1
60 hsa-miR-297 n408084 OCLN
61 hsa-miR-4647 n408084 OCLN
62 hsa‑miR‑3135b TCONS_l2_00020697‑XLOC_l2_010802 DOCK1
63 hsa‑miR‑323a‑3p TCONS_l2_00020697‑XLOC_l2_010802 DOCK1
64 hsa‑miR‑4462 TCONS_l2_00020697‑XLOC_l2_010802 DOCK1
65 hsa‑miR‑4726‑5p TCONS_l2_00020697‑XLOC_l2_010802 DOCK1
66 hsa‑miR‑6760‑5p TCONS_l2_00020697‑XLOC_l2_010802 DOCK1
67 hsa‑miR‑921 TCONS_l2_00020697‑XLOC_l2_010802 DOCK1
68 hsa‑miR‑619‑5p TCONS_00029068‑XLOC_013994 CDKN1A
69 hsa-miR-3135b NR_024387 ARHGEF12
70 hsa-miR-4462 NR_024387 ARHGEF12
71 hsa-miR-654-3p NR_024387 ARHGEF12
72 hsa-miR-7845-5p NR_024387 ARHGEF12
73 hsa-miR-3912-5p TCONS_00008436-XLOC_003882 PHLPP1
74 hsa-miR-4646-5p TCONS_00008436-XLOC_003882 PHLPP1
75 hsa-miR-6760-5p TCONS_00008436-XLOC_003882 PHLPP1
76 hsa-miR-7845-5p TCONS_00008436-XLOC_003882 PHLPP1
77 hsa-miR-297 ENST00000452532 OCLN
78 hsa-miR-4786-5p n339695 CLDN1
79 hsa‑miR‑4726‑5p n332799 DOCK1
80 hsa‑miR‑127‑5p n338895 PIK3CG
81 hsa‑miR‑378e n338895 PIK3CG
82 hsa‑miR‑5585‑3p n338895 PIK3CG
83 hsa‑miR‑6760‑5p n338895 PIK3CG
84 hsa‑miR‑7845‑5p n338895 PIK3CG
85 hsa-miR-297 TCONS_00022673-XLOC_010971 OCLN
86 hsa-miR-3138 TCONS_00022673-XLOC_010971 OCLN
87 hsa-miR-4647 TCONS_00022673-XLOC_010971 OCLN
88 hsa-miR-4786-5p TCONS_00022673-XLOC_010971 OCLN
89 hsa-miR-619-5p TCONS_00022673-XLOC_010971 OCLN
90 hsa-miR-7-5p TCONS_00022673-XLOC_010971 OCLN
91 hsa-miR-767-5p TCONS_00022673-XLOC_010971 OCLN
92 hsa-miR-7844-5p TCONS_00022673-XLOC_010971 OCLN
93 hsa‑miR‑3138 TCONS_00024504‑XLOC_011823 CDKN1A
94 hsa‑miR‑4677‑3p TCONS_00024504‑XLOC_011823 CDKN1A
95 hsa‑miR‑619‑5p TCONS_00024504‑XLOC_011823 CDKN1A
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miRNA-lncRNA-mRNA interaction network (data not shown). 
In this network, we got 148 miRNAs targeted lncRNAs, and 
these 148 lncRNAs were identified as ceRNAs and listed 
in Table Ⅱ. 
Biological role prediction of lncRNAs function as ceRNAs in 
CLDN5‑overexpressing hCMEC/D3 cells. GO and pathway 
analysis were applied to analyze the significant function and 
pathway of the mRNAs that contained in the 1049 feed-forward 
loop networks. Go analysis results showed that upregulated 
and downregulated mRNA respectively, were involved in 
122 and 81 items significant functions (P‑value <0.05, data 
not shown). The pathway analysis revealed that there were 29 
and 6 significant pathways corresponding to the up and down 
regulated mRNAs separately (P-value <0.05, data not shown). 
Further analysis indicated there are 10 mRNAs that 
contained both in the significant function and pathway 
(Table Ⅲ), and they participated in 95 feed‑forward 
loop networks. The miRNAs, lncRNAs, and mRNAs in 
95 feed‑forward loop are listed in Table Ⅳ. 
The biological roles of 27 lncRNAs acting as ceRNAs were 
predicted through GO and pathway analysis of 10 mRNAs in 
the miRNA-lncRNA-mRNA interaction network. In addi-
tion, the results indicated that 10 mRNAs participated in 
6 up regulated and 5 downregulated pathways involving in 
diverse biological processes, including tight junction, focal 
Figure 3. Function prediction of the ceRNAs based on pathway and GO analysis of mRNAs located in miRNA-lncRNA-mRNA interaction network. 
(A) The pathway analysis showed the 6 upregulated and 5 downregulated signaling pathways (P<0.05), and (B) GO analysis showed the 10 upregulated and 
5 down regulated functions (P<0.05).
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adhesion and cell adhesion molecules, and 10 upregulated 
and 5 downregulated functions that containing cell adhesion, 
heterophilic cell-cell adhesion, cell growth, cell apoptosis, etc 
(Fig. 3). 
As a consequence, we predicted the important roles of the 
27 ceRNAs in CLDN-5-overexpressing hCMEC/D3 cells.
Quantitative real‑time RT‑PCR (qRT‑PCR) analysis 
of the distinctive expression of miRNAs, lncRNAs, and 
mRNAs in hCMEC/D3 cells with overexpressed CLDN5. 
To validate the results of microarray analysis, we selected 
5 miRNAs, 5 mRNAs, and 5 lncRNAs with larger fold-
change from the microarray results and analyzed their 
expression levels by qRT-PCR in pLL3.7-CLDN5 and 
pLL3.7 hCMEC/D3 cells. Our results confirmed the findings 
of the miRNAs, lncRNAs and mRNAs microarray dataset 
(Fig. 4A).
Based on the analysis of 95 miRNA-lncRNA-mRNA 
feed‑forward loops in Table Ⅳ, we evaluated the expression 
levels of 3 miRNA, 3 lncRNA, and 3 mRNA that are respectively 
located in 3 feed-forward loops. The average expression level 
of miR‑127‑5p was significantly increased, while miR‑4786‑5p 
and miR-297 were reduced in CLDN5-overexpressing 
hCMEC/D3 cells compared with control hCMEC/D3 cells. 
Analysis showed relatively high expression of miR-127-5p and 
low expression of n338895 and PIK3CG, and low expression 
of miR-4786-5p and miR-297 and high expression of n339695, 
TCONS_00022673-XLOC_010971 and CLDN1, OCLN 
(Fig. 4B). The 3 feed-forward loops detection by qRT-PCR are 
represented in Fig. 4C.
Table IV. Functional prediction of the lncRNA ceRNAs based on pathway and GO analysis of mRNAs that locate together in the 
miRNA-lncRNA-mRNA feed-forward loop.
No. mRNA Pathway GO
  1 IGFBP3 P53 signaling Negative regulation of cell proliferation
   Regulation of cell growth
   Negative regulation of protein phosphorylation
   Apoptotic process
  2 PIK3CG Focal adhesion  Negative regulation of apoptotic process
  Regulation of actin cytoskeleton
  Proteoglycans in cancer
  PI3K‑Akt signaling
  3 CDKN1A P53 signaling  Negative regulation of cell proliferation/cell growth
  Pathways in cancer Intrinsic apoptotic signaling
  Proteoglycans in cancer Negative regulation of cyclin-dependent protein 
   serine/threonine kinase activity
   Negative regulation of phosphorylation
   Negative regulation of apoptotic process
  4 CDKN1B PI3K‑Akt signaling  Negative regulation of apoptotic process
   Cell cycle arrest
  5 PHLPP1 PI3K‑Akt signaling  Apoptotic process
  6 ARHGEF12 Regulation of actin cytoskeleton  
  Proteoglycans in cancer 
  7 PPARD PPAR signaling pathway Apoptotic signaling
  Pathways in cancer
  8 CADM1 Cell adhesion molecules Homophilic cell adhesion
   Apoptotic process
   Heterophilic cell-cell adhesion
   unidimensional cell growth
   Cell-cell junction organization
  9 CLDN1 Tight junction Cell adhesion
  Cell adhesion molecules Cell-cell junction organization
10 DOCK1 Focal adhesion; Apoptotic process
  Regulation of actin cytoskeleton 
11 OCLN Apoptotic process; Tight junction
  Cell-cell junction organization Cell adhesion molecules
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Discussion
In recent years, studies have confirmed the dysregulation of 
lncRNAs by acting as ceRNAs have profound implications 
for tumor metastasis. Reports demonstrate that lncRNAs as 
ceRNAs play an important role in blood-tumor barrier (BTB), 
and their dysfunction leads to the change of permeability of 
BTB. Several models have been proposed to explain how 
ceRNAs regulate BTB. Examples include lncRNA TuG1, 
NEAT1, XIST, MALAT1, which function in ceRNA manner 
to regulate expression of transcript factor (TF), such as 
HSF2, SOX5, FOXC1/ZO-2 or nuclear factor (NF) NFYA 
through targeting different miR-144, miR-181d-5p, miR-137, 
and miR-140. These TFs and NF regulate the expression of 
claudin-5, occludin, and ZO-1, and then impact the permea-
bility of BTB. Knockdown of lncRNAs TUG1, NEAT1, XIST, 
and MALAT1 resulted in increased the permeability of BTBs 
as well as decreased the expression of claudin-5, occludin, and 
ZO-1 (21-26). Although regulatory networks of ceRNA have 
now been shown to contribute to the permeability of BTB, the 
dysregulation of ceRNAs as a consequence of alterations in 
CLDN5 levels in BTB has not been previously investigated. 
Figure 4. Expression analysis of miRNA, lncRNA, and mRNA in pLL3.7-CLDN5-transfected and pLL3.7 control hCMEC/D3 cells. The expression level of 
(A) 5 miRNAs, 5 lncRNAs and 5 mRNAs, (B) 3 miRNAs, 3 lncRNAs and 3 mRNAs that are respectively located in (C) 3 feed-forward-loops were analyzed 
using qRT-PCR, with the GAPDH (for lncRNA and mRNA) and U6 (for miRNA) gene as an internal control. Error bars represent the standard errors of 
independent samples.
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In this study, we provide a comprehensive analysis of the roles 
of CLDN5 mediating the junctional and adhesion molecules, 
and signaling pathways through ceRNA interaction network in 
brain endothelial cells.
First of all, we used the Affymetrix GeneChip HTA 
2.0 Array to analyze the distinct lncRNAs and mRNAs 
in CLDN5-overexpressing hCMEC/D3 cells. The sample 
matched miRNA expression profiling was determined by the 
Affymetrix GeneChip miRNA 4.0 Array. We identified a set 
of 41 miRNAs, 954 lncRNAs, and 222 mRNAs that differently 
expressed between pLL3.7-CLDN5-transfected and pLL3.7 
control group. Such differentiation signified the potential roles 
of CLDN5 in cerebral vascular endothelial cells. 
Furthermore, we discussed the effect of miRNA competi-
tion on the regulation of both lncRNAs and mRNAs, as well 
as the implications of lncRNA function as ceRNA through 
constructing the complex miRNA-lncRNA-mRNA interaction 
network. The possible biology functions of these regulatory 
ceRNAs mainly include tight junction, focal adhesion, cell-cell 
adhesion, cell growth and apoptosis. To our knowledge, this is 
the first study to show the lncRNA acting as ceRNAs were 
associated with clautin-5 function in brain vascular endothe-
lial cells. 
Our qRT‑PCR expression analysis confirmed there are a 
series of miRNAs, lncRNAs, and mRNAs aberrantly expressed 
in the CLDN5-overexpressing hCMEC/D3 cells, which indi-
cated that the differently expressed non-coding and coding 
RNAs might be characteristics regulated by CLDN5. 
The expression of miR-127 was found to be upregulated, 
whereas miR-4786-5p and miR-297 were downregulated 
by CLDN5 overexpression. CLDN5 mediated interactions 
between metastasis tumor cells and brain endothelial cells. 
Recent studies showed miR-127 was aberrantly down-
regulated and acted as a functional tumor suppressor in several 
brain metastatic tumors, such as breast cancer (27), osteosar-
coma (28), lung cancer (29), hepatocellular carcinoma (30), 
while miR-297 acts as an oncogene and is upregulated in 
lung adenocarcinoma and osteosarcoma (31,32). Based on the 
findings obtained above, increased miR‑127 and decreased 
miR-297 expression levels in claudin-5-overexpressing brain 
vascular endothelial cells can make BBB impermeable and 
reduce brain metastasis from cancer. 
The PIK3CG, CLDN1 and OCLN mRNA regulated by 
ceRNA play key roles in the BBB. PIK3CG participates in 
the PI3K‑Akt signaling pathway involved in regulation of 
numerous important cell processes including cell growth, 
differentiation, and metabolism. PI3K also was found to be 
among a couple of genes that were specifically altered in 
brain metastases of various tumor entities (33,34), confirming 
previous reports that found specific alterations of the PI3K‑Akt 
pathway in melanoma (35) and non-small lung cancer (36) 
brain metastases. The results of our study suggest that the 
PI3K‑Akt pathway might be a promising target to prevent 
brain metastases by overexpression of claudin-5 through 
ceRNA. Occludin, claudin-1, and claudin-5 are all TJ proteins, 
and they interact with other junctional proteins and play an 
important role in several pathologies, including tumor brain 
metastasis (37,38). Our findings are particularly interesting in 
the dysregulated expression of CLDN1 and OCLN mRNA, in 
conjunction with the high CLDN5 levels. 
Overall, our study identified and analyzed lncRNA func-
tion as ceRNA in CLDN5-overexpressing cerebral vascular 
endothelial cells, and in which ceRNA works as a downstream 
effector of the CLDN5 to strengthen several signaling path-
ways and mediate its role in maintaining BBB permeability. 
understanding these ceRNA regulating networks would 
advance the development of prevention and therapy strategies 
for tumor brain metastasis.
Our findings indicated CLDN5 plays a key role in regulating 
BBB permeability through ceRNA network, so the activation 
of CLDN5 can inhibit tumor brain metastasis, which would 
be applied in medical treatment. Recent reports demonstrated 
that some proteases degrade tight junction protein, including 
CLDN5, and their inhibitor or antagonist prevents degra-
tion of tight junction protein and attenuates BBB disruption. 
Examples include telomerase (39,40), and matrix metallopro-
teinases (MMPs) (41). Several models have been proposed to 
explain how telomerase regulated tight junction protein. First, 
telomerase activity may affect CLDN5; moreover AZT as an 
inhibitor of telomerase could modulate CLDN5 expression; at 
last, catalytic component of the telomerase holoenzyme may 
affect wnt signaling pathways (40). Earlier studies have shown 
that MMPs and their inhibitors-TIMPs play an essential role in 
the permission of drugs to cross the BBB (42,43).
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